These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 11478352

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Intravenous aminoglycoside usage and monitoring of patients with cystic fibrosis in Australia. What's new?
    Soulsby N, Bell S, Greville H, Doecke C.
    Intern Med J; 2009 Aug; 39(8):527-31. PubMed ID: 19220547
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Is there a multinational consensus of tobramycin prescribing and monitoring for cystic fibrosis? Survey of current therapeutic drug monitoring practices in USA/Canada, UK/Ireland, and Australia/New Zealand.
    Larcombe R, Coulthard K, Eaton V, Tai A, Reuter S, Ward M.
    Eur J Hosp Pharm; 2024 Jun 21; 31(4):301-306. PubMed ID: 36600520
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Extended-interval aminoglycoside administration for children: a meta-analysis.
    Contopoulos-Ioannidis DG, Giotis ND, Baliatsa DV, Ioannidis JP.
    Pediatrics; 2004 Jul 21; 114(1):e111-8. PubMed ID: 15231982
    [Abstract] [Full Text] [Related]

  • 7. Once daily versus multiple daily dosing with intravenous aminoglycosides for cystic fibrosis.
    Tan K, Bunn H.
    Cochrane Database Syst Rev; 2000 Jul 21; (4):CD002009. PubMed ID: 11034740
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: V. Aminoglycosides.
    Young DC, Zobell JT, Stockmann C, Waters CD, Ampofo K, Sherwin CM, Spigarelli MG.
    Pediatr Pulmonol; 2013 Nov 21; 48(11):1047-61. PubMed ID: 24000183
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Distribution and elimination of tobramycin administered in single or multiple daily doses in adult patients with cystic fibrosis.
    Aminimanizani A, Beringer PM, Kang J, Tsang L, Jelliffe RW, Shapiro BJ.
    J Antimicrob Chemother; 2002 Oct 21; 50(4):553-9. PubMed ID: 12356801
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The pharmacokinetics and toxicity of morning vs. evening tobramycin dosing for pulmonary exacerbations of cystic fibrosis: A randomised comparison.
    Prayle AP, Jain K, Touw DJ, Koch BC, Knox AJ, Watson A, Smyth AR.
    J Cyst Fibros; 2016 Jul 21; 15(4):510-7. PubMed ID: 26282839
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Pharmacokinetics of once and twice daily dosing of intravenous tobramycin in paediatric patients with cystic fibrosis.
    Brigg Turner R, Elbarbry F, Biondo L.
    J Chemother; 2016 Aug 21; 28(4):304-7. PubMed ID: 26430825
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics and safety of tobramycin after once-daily administration in patients with cystic fibrosis.
    Bates RD, Nahata MC, Jones JW, McCoy K, Young G, Cox S, Barson WJ.
    Chest; 1997 Nov 05; 112(5):1208-13. PubMed ID: 9367459
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.